rhEPO in China: Key market research findings
- Perseverance of CKD and dialysis patient population drives market growth
- HIV segmentto exhibit the fastest growth rate during the forecast period
- Key vendors – 3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genentech, Kyowa Hakko Kirin, and Shandong Kexing
Technavio’s market research analysts predict the rhEPO market in China to grow at a CAGR of around 16% between 2016 and 2020. The increase in the chronic kidney disease (CKD) and dialysis patient population in the region are the primary driving force behind growth in the market. This rise in the number of CKD patients can be attributed to the increase in China’s aging population, which is the world’s largest. The population control measures undertaken by the country such as the one-child per family policy is resulting in a growing population above the age of 50 years. During 2015, the hospital end-user segment accounted for around 60% of the market space to become the dominant shareholder in the recombinant human erythropoietin (rhEPO) market in China. Hospitals are the primary customers for erythropoietin (EPO) drugs as they find application in the treatment of anemia due to renal diseases or cancers and chemotherapy drugs. Furthermore, dialysis procedures in renal diseases and chemotherapy for cancers can be provided to patients only in hospital settings.
The new market research report from Technavio presents a breakdown and analysis of rhEPO segments based on application.
“The penetration of rhEPO drugs in grade I and II hospitals is an ongoing trend in the market. Most rhEPO drugs are increasingly used in grade III hospitals as they offer specialized services to treat cancer and CKD. However,several companies are attempting to promote the use of these drugs in grade I and II hospitals as this help increase the market share of the drugs, thereby boosting growth in the market. For instance, with the acquisition of SEPO from Sciprogen, the use of this drug is being promoted in lower tier hospitals,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
Currently, the human immunodeficiency virus (HIV) segment is the fastest-growing segment of the rhEPO market in China. HIV results in anemia either as a manifestation of the disease or as a result of the medications used to treat it. Hematological abnormalities stemming from the impaired blood cellular components formation, immune-mediated reduction in the blood cells, and altered coagulation mechanisms are common in people with the disease.
The key vendors in the rhEPO market in China include 3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genentech, Kyowa Hakko Kirin, and Shandong Kexing. Due to the presence of numerous small and large vendors, the rhEPO market in China is highly competitive and fragmented. The rising prevalence of renal diseases and cancer has led to the increasing uptake of rhEPO drugs in the last few years. With companies looking to manufacture drugs that can effectively treat and cure anemia, in addition to exhibiting a high safety and efficacy profile, the prospects for growth in this market will have a positive outlook until the end of the forecast period. Vendors are also likely to engage in strategic alliances to market and manufacture drugs.
A more detailed analysis is available in the Technavio report, rhEPO market in China 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
